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Bullous eruption on the posterior thigh
James Studdiford, MD; Amber Stonehouse, MD
Thomas Jefferson University Hospital, Department of Family and Community
Medicine, Philadelphia, Pa
A healthy 11-year-old girl visited her family physician with a lesion on her right posterior
thigh. The lesion was a 1-cm plaque that was tender, firm, erythematous, and indurated,
with a central pustule. It had been present for 3 days; it was noticed by the patient after
returning from a camping trip in southeastern Pennsylvania. The pustular area was
incised, drained, and cultured, and the patient was started on cephalexin.
Two days later, the lesion did not improve, showing increased induration, erythema, and
blistering. The patient went to the emergency department with an 8 cm by 6 cm
coalescence of thin-walled vesicles and bullae with surrounding erythema (FIGURES 1
AND 2). A thick, honey-yellow adherent crust covered the eroded center of the lesion.
The girl’s temperature was 37.1°C, and she reported no burning, pain, or pruritus. She
had full range of motion of her right hip and knee, and no lymphadenopathy was
detected. Her white blood cell count was normal; blood and wound cultures were taken.

FIGURE 1
Bullous eruption on the thigh

Large coalescence of thin-walled bullae on an
erythematous base located on the right posterior
thigh.

FIGURE 2
Close-up

Large coalescence of thin-walled bullae with a thick,
honey-yellow adherent crust covering the eroded center
of the lesion.
 What is the most likely diagnosis?
 How would you empirically treat this condition?
 Diagnosis: Bullous impetigo, caused by methicillinresistant S aureus
Impetigo is a highly contagious superficial skin infection, with peak incidence among
children aged 2 to 6 years.1,2 Nonbullous impetigo (70% of cases) is caused by
Staphylococcus aureus or betahemolytic Streptococcus.3 Bullous impetigo is almost
always caused by S aureus. Epidermolytic toxins produced by phage group II strains
cause loss of cell adhesion in the stratum granulosum due to proteolytic attack of
desmoglein 1, resulting in bullae.4
Bullous impetigo may occur after minor skin injury, such as an insect bite, abrasion, or
dermatitis.
Lesions generally start as small vesicles on the face, buttocks, extremities, or perineum,
and may progress to a coalescence of thin-roofed bullae. The flaccid bullae rupture
easily, draining serous or purulent fluid.
Lesions are usually painless, and systemic findings are rare. Lymphadenopathy is rare in
bullous impetigo but common in nonbullous impetigo. The disease is generally selflimited and complications are uncommon. However, ecthyma (ulcerative impetigo) may
result from an untreated impetigo infection.5

Differential diagnosis
The differential diagnosis for bullous impetigo is broad, and may include allergic contact
dermatitis, herpes simplex, herpes zoster, pemphigus foliaceus, bullous pemphigoid,
pemphigus vulgaris, and (in this case specifically) erythema migrans.
Allergic contact dermatitis is a delayed hypersensitivity reaction, usually caused by skin
contact with an allergen. Lesions can be vesicular, edematous, erythematous, and pruritic.
In this case, the patient did not have allergen exposure or a pruritic lesion.
Herpes zoster is a reactivation of the varicella zoster virus, characterized by stabbing,
neuritic pain in a dermatomal distribution. Clear vesicles on an erythematous, edematous
base distributed along a dermatome constitutes the classic appearance. This was not the
case with this patient.
Pemphigus foliaceous is an autoimmune intraepidermal blistering disease with lesions
occurring on the face, scalp, chest, and upper back.5 Intact blisters are not commonly
seen. The vesicle roof is very thin and ruptures easily, forming broad areas of crust. Skin
biopsy reveals intraepidermal bulla or acantholysis in the upper epidermis.
Pemphigus vulgaris is also an autoimmune blistering disease that affects the skin and
mucous membranes. It is generally seen among patients aged >40 years.
Bullous pemphigoid is an autoimmune disorder presenting with chronic eruption of
erythematous, papular, urticaria lesions often evolving into bullae. Childhood cases are
rare. Biopsy of the lesions demonstrates subepidermal bulla with an infiltration of
eosinophils within the dermis.5
Erythema migrans with central vesiculation must be considered given the patient’s
camping trip. Recent evidence shows that erythema migrans with central redness
accounts for most cases in areas endemic for Lyme disease. Only 10% of the patients
with early Lyme disease show the classic bulls-eye lesion with concentric erythematous
rings and central clearing. Vesiculation can occur in up to 30% of lesions.6
Staphylococcus aureus and antibiotic resistance
As many as 61% of community-acquired methicillin-resistant S aureus (MRSA)
infections are initially treated only with beta-lactam antibiotics, to which they are
resistant.7 Risk factors for community-acquired MRSA infection include day-care
attendance, recent hospitalization, recent antibiotic use, chronic illness, and frequent
health care visits.8 A growing number of cases are reported among patients without risk
factors.
Community-acquired MRSA isolates are usually genetically different from nosocomial
isolates, and have been relatively susceptible to non–beta-lactam antibiotics. These

strains vary substantially, however, and it is important to check the susceptibility of the
isolate.
Virulent new strains of S aureus are infecting children—these strains have a novel
transpeptidase, which offers them a mechanism of resistance to beta-lactams different
from hospital-and community-acquired types.
Awareness of the local antimicrobial susceptibility patterns of community S aureus
isolates is also helpful. Oral antibiotics that have been successful include clindamycin,
minocycline, doxycycline, and trimethoprim-sulfamethoxazole. Cephalexin has no
therapeutic value in treating community-acquired MRSA.
Preventing disease spread in the patient and contacts
Preventive efforts should be directed at patients with recurrent episodes of MRSA skin
abscesses. Metabolic and immunologic screening should be performed to rule out
underlying disease processes causing increased risk for infection. In most cases these test
results are normal, and patients with recurrent MRSA skin abscesses should also be
empirically treated for presumed nasal carriage of MRSA.
Mupirocin ointment (Bactroban) should be applied to the nares twice daily for 5 days in
an effort to prevent recurrent self-inoculation and lateral transmission of MRSA.
Patients and families should also be instructed in hygienic measures such as daily
changing of underwear and personal use only of towels, washcloths, and sleepwear.
Fingernails should be kept short and clean. Open insect bites or superficial skin abrasions
should be kept clean and covered. Benefit from the daily use of antimicrobial soaps is
controversial.
Empiric treatment of impetigo: Consider a culture for MRSA
For localized impetigo, topical therapy with mupirocin 2% ointment 3 times a day for 10
days is usually adequate. A 10-day course of oral antibiotic therapy with dicloxacillin or
cephalexin is indicated in more widespread impetigo presumed to be methicillin-sensitive
S aureus. Azithromycin (Zithromax) or clarithromycin (Biaxin) may be given to patients
allergic to penicillin.
However, it is becoming increasingly important to consider community-acquired
methicillin-resistant S aureus species in cases such as this that do not respond to
traditional therapy. Hence, culture and sensitivity of all suspicious lesions is highly
suggested.
Patient’s treatment and recovery
In this case, the patient was diagnosed with bullous impetigo and admitted to the hospital.
She was started on intravenous clindamycin at 380 mg (30 mg/kg) every 8 hours.

Clindamycin was chosen because most cases of community-acquired MRSA in this
geographic area are resistant to trimethoprim-sulfamethoxazole and susceptible to
clindamycin.
Although doxycycline would have covered both community-acquired MRSA and Lyme
disease, we were less suspicious of Lyme given the physical exam of the patient, and we
were reluctant to start this patient on doxycycline due to the fact she did not have
complete maturation of her dentition.
Within 24 hours of intravenous clindamycin, the lesion was markedly improved and the
culture confirmed that the MRSA was sensitive to clindamycin. She was discharged on
oral clindamycin at 375 mg 3 times daily, to complete a 14-day course of therapy. The
lesion was completely resolved without recurrence within 2 weeks.
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